Hangzhou

Gsport Is Committed To Quality

Retrieved on: 
Wednesday, June 23, 2021
Hangzhou, Jiangnan, Yangtze River Delta

This commitment to quality extends throughout its operation, from employee satisfaction to robust manufacturing capabilities, in-depth R&D efforts, and committed customer service.

Key Points: 
  • This commitment to quality extends throughout its operation, from employee satisfaction to robust manufacturing capabilities, in-depth R&D efforts, and committed customer service.
  • Gsport is most well known as a manufacturer of athletic and kinesiology tapes.
  • Gsport is a subsidiary of Hangzhou GSPMED Medical Appliances Co., a parent company that has set a standard of excellence throughout its various business activities.
  • About Gsport: Gsport is a subsidiary of Hangzhou GSPMED Medical Appliances Co., which has been in operation for nearly twenty years.

Hangzhou International Event and Exhibition Culture Workshop & Innovation and Development Conference 2021 takes place in Hangzhou, China

Retrieved on: 
Monday, June 21, 2021
Cities in China, Yangtze River Delta, International Association for Energy Economics, Hangzhou, West Lake, Tourism in China, Zhejiang

HANGZHOU, China, June 21, 2021 /PRNewswire/ -- Hangzhou International Event and Exhibition Culture Workshop & Innovation and Development Conference 2021 (hereafter referred to as the "Conference") was held atWest Lake Expo Museum in Hangzhou, Zhejiang province, China on June 18, 2021.

Key Points: 
  • HANGZHOU, China, June 21, 2021 /PRNewswire/ -- Hangzhou International Event and Exhibition Culture Workshop & Innovation and Development Conference 2021 (hereafter referred to as the "Conference") was held atWest Lake Expo Museum in Hangzhou, Zhejiang province, China on June 18, 2021.
  • On the afternoon of June 18, IAEE announced the establishment of IAEE China Council in Hangzhou and held the first council meeting at Hangzhou Xinqiao Hotel.
  • Globally, China boasts the highest number of conferences and exhibitions professionals who have received the CEM designation at over 1,300.
  • The establishment of IAEE China Council in Hangzhou is expected to bring more opportunities to the local conference and exhibition sector.

First Patient Dosed in Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion

Retrieved on: 
Friday, June 18, 2021
Tyrosine kinase receptors, ROS1, Chemical compounds, Lung cancer, Orphan drugs, Organic compounds, Drugs, Entrectinib, Crizotinib

(AnHeart), a clinical stage oncology company focused on underserved patients in global markets, today announced that the first patient has been dosed in a Phase II basket trial of taletrectinib for solid tumors containing NTRK fusions ( NCT04617054 ).

Key Points: 
  • (AnHeart), a clinical stage oncology company focused on underserved patients in global markets, today announced that the first patient has been dosed in a Phase II basket trial of taletrectinib for solid tumors containing NTRK fusions ( NCT04617054 ).
  • Building upon the promising preliminary results in the Phase II trial for non-small cell lung cancer (NSCLC) with ROS1 fusions, we are moving forward with the Phase II trial of taletrectinib for NTRK fusion-driven solid tumors, said Bing Yan, MD, Co-founder and Chief Medical Officer of AnHeart.
  • We are very pleased to see that our partner AnHeart is advancing the Phase II trial of taletrectinib in NTRK fusion-driven solid tumors.
  • More information about the ongoing TRUST (Taletrectinib ROS1 LUng STudy) trial in ROS1 fusion positive NSCLC and the ongoing basket trial in NTRK fusion positive solid tumors of taletrectinib may be found by searching clinical trial identifiers NCT04395677 and NCT04617054, respectively at https://clinicaltrials.gov .

Happiness Biotech Entered Into Electric Vehicle Distribution Agreement With Geely's Subsidiary

Retrieved on: 
Thursday, June 10, 2021
Software, Jiangnan, Cities in China, Maple, WeChat, Ningbo, Nutraceutical, Dietary supplement, Hangzhou

According to the distribution agreement, Taochejun will become the sales agent for "Maple 80V" in Ningbo City and Hangzhou City.

Key Points: 
  • According to the distribution agreement, Taochejun will become the sales agent for "Maple 80V" in Ningbo City and Hangzhou City.
  • The Company has registered the trademark of Taochejun in China and launched the WeChat App of Taochejun in May 2021.
  • "We are very happy to cooperate with Maple Auto and reach an agreement regarding distribution of Maple automobiles.
  • Headquartered in Nanping, China, Happiness Biotech Group Limited has two business segments: nutraceutical and dietary supplements and e-commerce.

Hailiang Education Group Inc. Announces Results of Annual General Meeting of Shareholders for Fiscal Year 2021

Retrieved on: 
Wednesday, June 9, 2021
Cities in China, Sub-provincial cities in the People's Republic of China, Economy of New York City, NASDAQ, Hangzhou, Zhuji

HANGZHOU, China, June 9, 2021 /PRNewswire/ --Hailiang Education Group Inc. (Nasdaq: HLG) ("Hailiang Education" or the "Company"), an education and management services provider of primary, middle, and high schools in the PRC, announced today the results of the Company's 2021 Annual General Meeting of Shareholders ("AGM") held on June 9, 2021, at 10:00 a.m. local time in Zhuji, Zhejiang, China.

Key Points: 
  • HANGZHOU, China, June 9, 2021 /PRNewswire/ --Hailiang Education Group Inc. (Nasdaq: HLG) ("Hailiang Education" or the "Company"), an education and management services provider of primary, middle, and high schools in the PRC, announced today the results of the Company's 2021 Annual General Meeting of Shareholders ("AGM") held on June 9, 2021, at 10:00 a.m. local time in Zhuji, Zhejiang, China.
  • About Hailiang Education Group Inc.
    Hailiang Education (Nasdaq: HLG) is one of the largest primary, middle, and high school educational service providers inChina.
  • Hailiang Education adapts its education services based upon its students' individual aptitudes.
  • Hailiang Education is committed to making great effort to provide its students with greater opportunities to enroll in well-known domestic and international universities to further their education.

AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

Retrieved on: 
Monday, June 7, 2021
Chemical compounds, Organic compounds, Aromatic compounds, Tyrosine kinase receptors, Lung cancer, ROS1, Crizotinib, Non-small-cell lung carcinoma, Entrectinib, ALK inhibitor

The results were as follows:

Key Points: 
  • The results were as follows:
    In the crizotinib pre-treated patients (n=5), the ORR was 60% (3/5); and the DCR was 100% (5/5).
  • Our team is highly focused on completing patient enrollment for this phase II TRUST trial in Q3 2021, said Bing Yan, MD, Co-founder and Chief Medical Officer of AnHeart.
  • We sincerely thank the patients, their families and investigators in the TRUST trial and look forward to bringing taletrectinib to all ROS1 fusion positive patients in the near future upon approval.
  • Taletrectinib has shown good efficacy and safety results, which offers hope to patients with ROS1 fusion positive non-small cell lung cancer."

Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China

Retrieved on: 
Tuesday, June 1, 2021
Countries, Cities in China, Hangzhou, Jiangnan, Yangtze River Delta, East Asia, China

Under the terms of the agreement, Innovent will obtain exclusive rights to co-develop and commercialize taletrectinib in Greater China.

Key Points: 
  • Under the terms of the agreement, Innovent will obtain exclusive rights to co-develop and commercialize taletrectinib in Greater China.
  • AnHeart will continue to be responsible for the development of taletrectinib up to regulatory approval in mainland China and for supplying taletrectinib for both developmental and commercial purposes in Greater China.
  • We have been impressed with our partner's capability toadvance the global development of taletrectinib and we are excited to help bring taletrectinib to patients in Greater China.
  • AnHeart is headquartered in Hangzhou, China with offices in Beijing, Shanghai and has a subsidiary AnHeart Therapeutics Inc. in New York.

AnHeart Therapeutics and Innovent Biologics Announce Exclusive License Agreement for Taletrectinib in Greater China

Retrieved on: 
Tuesday, June 1, 2021
Hangzhou, Jiangnan, Yangtze River Delta, Royalty payment

Under the terms of the agreement, Innovent will obtain exclusive rights to co-develop and commercialize taletrectinib in Greater China.

Key Points: 
  • Under the terms of the agreement, Innovent will obtain exclusive rights to co-develop and commercialize taletrectinib in Greater China.
  • AnHeart will continue to be responsible for the development of taletrectinib up to regulatory approval in mainland China and for supplying taletrectinib for both developmental and commercial purposes in Greater China.
  • According to the agreement, AnHeart will receive an upfront payment, R&D fees, and potential milestone payments totaling $189 million in addition to tiered royalties based on annual net sales of taletrectinib in Greater China.
  • AnHeart is headquartered in Hangzhou, China with offices in Beijing, Shanghai and has a subsidiary AnHeart Therapeutics Inc. in New York.

Ebang International: Crackdown on Bitcoin mining has no direct or immediate impact on the company

Retrieved on: 
Friday, May 28, 2021
Payment systems, Cryptocurrencies, Digital currencies, Bitcoin, Currency, Exonumia, Mining

As China's central government recently intensified a crackdown on bitcoin mining and trading, Ebang International Holdings, Inc. stressed in a latest statement that the crackdown has no direct or immediate impact on the company by highlighting for its shareholders the distinctions between its business and the impact of the China governments policy.

Key Points: 
  • As China's central government recently intensified a crackdown on bitcoin mining and trading, Ebang International Holdings, Inc. stressed in a latest statement that the crackdown has no direct or immediate impact on the company by highlighting for its shareholders the distinctions between its business and the impact of the China governments policy.
  • The complete statement is as follows:
    Mining business: When we first announced our mining business, we only considered overseas mining farms, therefore the recent crackdown on bitcoin mining within China has no direct or immediate impact on the company.
  • We will activate our mining machine custody business as soon as our overseas mining farms finish construction.
  • Accordingly, the Chinese governments crackdown on trading has no impact on the company and its prospects.

UTStarcom Names Hua Li as New Chief Executive Officer and Announces Changes to Its Board of Directors

Retrieved on: 
Monday, May 24, 2021
Articles, Board of directors, Business law, Committees, Corporate law

Prior to that, Mr. Li served as the Deputy General Manager of Jiangsu Tongding Broadband Co., Ltd.

Key Points: 
  • Prior to that, Mr. Li served as the Deputy General Manager of Jiangsu Tongding Broadband Co., Ltd.
  • Mr. Li obtained a diploma of Communication Technology from the University of Electronic Science and Technology of China through Online education in 2017.
  • Dr. Huang served as the Chief Executive Officer and a member of the Companys Board of Directors since January 1, 2021 and the Acting Chief Executive Officer since March 2020.
  • It is an honor to be appointedto the board of directors andserve as Chairman of the Board.